Compare · Head-to-head
Thymosin Beta-4 vs Vasoactive Intestinal Peptide.
Evidence, risk, regulatory flags, cost, and vendor coverage compared side by side. We don’t sell peptides — we help you choose between them.
Which should you research first?
Start with Thymosin Beta-4, then use the table to confirm fit.
Thymosin Beta-4 is the cleaner first read based on the current evidence, risk, and regulatory data stored for this pair. The right answer can still change if your goal, sport testing status, vendor constraints, or monitoring tolerance makes the other option a better fit.
Comparison next step
Personalize this head-to-head.
Take the quiz before converting a comparison into a compound, vendor, or protocol decision.
01· Subject
Thymosin Beta-4
Actin-sequestering peptide with clinical data in ophthalmic wound healing and preclinical tissue repair.
01 · At a glance
| Decision factor | Thymosin Beta-4 | Vasoactive Intestinal Peptide |
|---|---|---|
| Primary fit | tissue repair & recovery and immune support comparisons | tissue repair & recovery and immune support comparisons |
| Evidence | Tier B-C | Tier C |
| Risk | med-high | medium |
| Experience level | intermediate | advanced |
| Budget tier | mid | premium |
| Administration route | topical, subcutaneous | subcutaneous, intravenous |
02 · Use case & timing
| Decision factor | Thymosin Beta-4 | Vasoactive Intestinal Peptide |
|---|---|---|
| Goal fit | Tissue Repair & Recovery, Immune Support | Tissue Repair & Recovery, Immune Support |
| What users compare it for | Ophthalmic: improved corneal epithelial healing. Systemic: wound healing signals in preclinical models. | Vasodilation, pulmonary vascular effects, and anti-inflammatory signaling in narrow research contexts. |
| Onset timeline | Corneal healing studies: days to weeks; systemic repair claims are less well-timed. | Hemodynamic effects occur within minutes; sustained protocols are needed for longer exposure. |
| Main tradeoff | Evidence and product availability can still be uneven, so documentation matters more than hype. | Evidence and product availability can still be uneven, so documentation matters more than hype. |
03 · Safety & restrictions
| Decision factor | Thymosin Beta-4 | Vasoactive Intestinal Peptide |
|---|---|---|
| Adverse effects | Human ophthalmic safety reported as acceptable in trials; systemic safety requires caution. | Hypotension, flushing, tachycardia, headache, diarrhea, and infusion intolerance. |
| Contraindications | Limited formal contraindication data. | Avoid in hypotension, hypovolemia, or settings where strong vasodilation is unsafe. |
| Interaction notes | Limited formal interaction studies; treat as unknown outside studied settings. | Likely additive with other blood-pressure-lowering or vasodilating agents. |
| Regulatory status | Investigational | Not approved |
| FDA flag | FDA compounding caution | FDA status unclear |
| WADA status | WADA S2 | Not listed |
04 · Age & monitoring
| Decision factor | Thymosin Beta-4 | Vasoactive Intestinal Peptide |
|---|---|---|
| Supported age ranges | No age guidance yet | No age guidance yet |
| Life-stage note | Not yet documented | Not yet documented |
| Monitoring burden | Not specified | Not specified |
| Follow-up cadence | Not yet documented | Not yet documented |
05 · Cost & sourcing
| Decision factor | Thymosin Beta-4 | Vasoactive Intestinal Peptide |
|---|---|---|
| Typical cycle cost | $192.00 | No reliable estimate yet |
| Estimated monthly cost | $96.00 | No reliable estimate yet |
| Cost confidence | High confidence | No estimate |
06 · Before you buy
| Decision factor | Thymosin Beta-4 | Vasoactive Intestinal Peptide |
|---|---|---|
| Tracked vendor listings | 1 listing | 0 listings |
| Sourcing note | Product format varies by listing, so double-check route, concentration, and presentation. | No tracked product page yet, so sourcing takes more manual review. |
| Stack-friendly? | Usually stack-friendly | Usually stack-friendly |
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Still deciding
Get a plan tailored to you.
The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.